Navigation Links
Labopharm announces details for first quarter results conference call and annual meeting
Date:4/23/2009

LAVAL, QC, April 23 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the dates and times of its first quarter fiscal 2009 results conference call and Annual Meeting of Shareholders.

First Quarter Results Conference Call

On Thursday, May 7 at 8:30 a.m. (ET) Labopharm will host a conference call to discuss its first quarter 2009 financial results. Labopharm will report its first quarter 2009 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3420 or 1-800-732-0232. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, May 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21303738 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

Annual Meeting of Shareholders

Labopharm will hold its Annual Meeting of Shareholders on Thursday, May 7 at 11:00 am ET at the Montreal Museum of Fine Arts, Maxwell-Cummings Auditorium, 1379 Sherbrooke Street West, Montreal, Quebec.

A live webcast of the meeting will be available at www.labopharm.com. Please connect at least 15 minutes prior to the meeting to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of ... and evaluation leaders with decades of experience who remain current practitioners in the ... healthcare system, there is a renewed demand for versatile, data-driven leadership.The American University’s ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... applications. However, choosing the right method is paramount to success. Selecting an inappropriate ... in situations where multiple persons use the same equipment. Rare or expensive substances ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) ... services for women of all ages. The staff of Gynecology Associates of ... services from routine health screenings to diagnosing and treating female concerns including menopause, ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring ... creation of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. ... over nineteen, a pastor for over fifteen years. He is a graduate of N.C. ...
(Date:1/22/2017)... , ... January 22, 2017 , ... Medical lab ... results. Often the results of a simple test will take days to arrive to ... Test Now offers customers direct access to their lab tests, bypassing the cost and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan 23, 2017 Research and Markets has ... & Trends - Product - Forecast to 2025" report to their ... Report Highlights: ... future market trends to identify the investment opportunities Market ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... Ahead of today,s trading session, Stock-Callers.com draws investors, attention ... the close: Kite Pharma Inc. (NASDAQ: KITE ), BioPharmX ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to a ... January 20 th , 2017, down on the day by about ... now at: ...
(Date:1/23/2017)... SAN FRANCISCO , January 23, 2017 The global  ... USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated ... and psychotherapies has resulted in the declining demand for antidepressants in the recent ... ... Grand View Research Logo ...
Breaking Medicine Technology: